Home > Insider Trading > Filing (0001181431-15-007558)

Filing Details

Accession Number:: 0001181431-15-007558
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-05-27 18:39:20
Reporting Period:: 2015-05-26

Filing Date:: 2015-05-27
Accepted Time:: 2015-05-27 18:39:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501756	Avalanche Biotechnologies Inc.	[AAVL]	Biological Products, (No Disgnostic Substances) (2836)	205258327

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1504491	Paul Wachter	C/O Avalanche Biotechnologies, Inc. 1035 O'Brien Drive, Suite A Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-05-26	786	$36.52	41,143	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-05-26	304	$37.59	40,839	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2015-05-26	102	$38.30	40,737	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,000	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
This transaction was executed in multiple trades in prices ranging from $36.020 to $37.020, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares are held directly by the Wachter Family Trust.
This transaction was executed in multiple trades in prices ranging from $37.025 to $38.020, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $38.050 to $38.620, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.